F-star CEO: Revamped Merck KGaA Pact Is First Step In New Corp Direction
Executive Summary
F-star CEO tells Scrip reconfiguring biotech’s pact with Merck KGaA on oncology asset FS118 is UK group’s first big move towards a wholly owned portfolio strategy.
You may also be interested in...
Deal Watch: Parvus Signs Second Big Pharma Alliance, With Genentech
Two years after its first big Navacim-based tie-up with Novartis, Parvus could earn beyond $800m in autoimmune R&D pact with Genentech. Iconic licenses ADC tech from Zymeworks, then out-licenses lead candidate to Exelixis.
Merck KGaA Keen To Remain Key Player In MS Now And In Future
The German company is predicting sales in mid-triple-digits in 2019 for Mavenclad, its multiple sclerosis drug which has just been launched in the US, and has highlighted more promising MS data for its BTK inhibitor evobrutinib.
Patient-Centric: Evotec’s CSO Explains R&D Strategy
Evotec’s multimodality approach to drug discovery landed the biotech two new discovery collaborations this week, underscoring its emphasis on patient-driven data.
Need a specific report? 1000+ reports available
Buy Reports